ArticleJournal of neuro-oncology2026
Magnetic resonance imaging features differentiate histologic and molecular subtypes of glioblastoma IDH-Wild type CNS WHO grade 4.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioblastoma IDH-wild type, CNS WHO grade 4 (GBM) can be diagnosed on the basis of histologic features (histological-GBM) or molecular features (molecular-GBM). Only few studies report neuroimaging features of GBM in its modern classification, and none have controlled for surgical status or used multiple logistic regression analysis to determine unique predictors. Our study aimed to validate MRI features that distinguish histological-GBM and molecular-GBM.
methodsWe analyzed a training cohort (n = 255) and validation cohort (n = 44) of GBM cases, classified according to the 2021 WHO Classification of Tumors of the CNS. For the training cohort, univariate and multiple logistic regression analyses determined if MRI metrics (contrast enhancement, ring-enhancement, vasogenic edema, multifocal tumor, lesion diameter, hemorrhage, number of lobes, and normalized ADC) and surgery type (biopsy vs. resection) predicted GBM-type (histological vs. molecular). A reduced multiple logistic regression model was constructed and applied to the validation dataset.
resultsThere were 231 histological-GBMs and 24 molecular-GBMs in the training cohort. Multiple logistic regression analysis including both MRI metrics and surgery type showed that contrast enhancement (OR 7.83 [95%CI: 1.23–49.68], p = 0.029), ring enhancement (OR 5.98 [95%CI: 1.09–32.93, p = 0.040), and normalized ADC (OR 0.78 [95%CI: 0.62–0.99], p = 0.039) differed between histological and molecular-GBM. Analysis of the validation dataset using the unique training dataset-derived predictor variables (contrast-enhancement, ring-enhancement, and normalized ADC) found correct classification of each histological and molecular-GBM.
conclusionMolecular and histological-GBM exhibit distinct MRI phenotypes independent of surgical status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.